← All trials
NCT01306461
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2011
- Primary completion
- Apr 1, 2012
- Completion date
- May 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 401
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Santen Inc.Lead sponsor
- Medical University of ViennaOverall official - principal investigator
- University Mulitiprofile Hospital for Active Treatment Sv.Georgi, BulgariaOverall official - principal investigator
- P. Stradina Clinical University Hospital, LatviaOverall official - principal investigator
- Universidad Complutense de MadridOverall official - principal investigator
- Semmelweis UniversityOverall official - principal investigator
- Charles UniversityOverall official - principal investigator
- Santen Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.